CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) — Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced…
Tag: Oncology
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) — Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on October 1st, 2020, for its…